IP Library Patent Application 11176253
Patent Application
App. No. 11/176,253

Novel clock gene promoter

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/176,253
Abstract

The present invention discloses a Period2 gene promoter, a construct containing the promoter and a reporter gene, a cell containing the construct, a transgenic animal harboring the construct, and a method for screening a substance which controls expression or oscillatory expression of a biological clock gene. The screening method uses the above cell, a suprachiasmatic nucleus section or peripheral tissue of the above transgenic animal or the above transgenic animal.

Claims (21)

1 - 10 . (canceled)

11 . An isolated DNA which maintains a basal promoter activity and has a promoter activity transcriptionally-activated by a BMAL1/CLOCK heterodimer, which comprises the nucleotide sequence consisting of nucleotides at positions 3,820 to 6,068 in the nucleotide sequence represented by SEQ ID NO:2.

12 . The DNA according to claim 11 , which consists of the nucleotide sequence of nucleotides at positions 3,820 to 6,068 in the nucleotide sequence represented by SEQ ID NO:2.

13 . A construct which comprises the DNA according to claim 11 or 12 operably linked to a reporter gene.

14 . A cell which comprises the construct according to claim 13 .

15 . A method for screening a substance which controls expression of Period2 gene, comprising the steps of:

allowing the cell according to claim 14 to contact with a substance to be tested, and

measuring activity of the reporter gene.

16 . A transgenic rat or mouse transfected with the construct according to claim 13 , and wherein the suprachiasmatic nucleus and/or peripheral tissues of the rat or mouse exhibit the function of reporter gene expression.

17 . The transgenic rat according to claim 16 .

18 . The transgenic rat or mouse according to claim 16 , wherein the reporter gene is one member selected from the group consisting of a gene encoding luciferase, a gene encoding secretion type alkaline phosphatase (SEAP), a gene encoding green fluorescent protein (GFP), a gene encoding chloramphenical acetyltransferase (CAT), a gene encoding β-glucuronidase (GUS), a gene encoding β-D-galactosidase and a gene encoding aequorin.

19 . The transgenic rat according to claim 17 , wherein the reporter gene is one member selected from the group consisting of a gene encoding luciferase, a gene encoding secretion type alkaline phosphatase (SEAP), a gene encoding green fluorescent protein (GFP), a gene encoding chloramphenical acetyltransferase (CAT), a gene encoding β-glucuronidase (GUS), a gene encoding β-D-galactosidase and a gene encoding aequorin.

20 . A method for screening a substance which controls expression and/or oscillatory expression of Period2 gene, comprising the steps of:

allowing the cell according to claim 14 to react with a substance to be tested, and

measuring activity of the reporter gene for oscillatory expression of the Period2 gene.

21 . A method for screening a substance which controls expression and/or oscillatory expression of Period2 gene, comprising the steps of:

administering a substance to be tested to the transgenic rat or mouse according to claim 16 , and

measuring activity of the reporter gene in the suprachiasmatic nucleus of the animal for oscillatory expression of the Period2 gene.

22 . A method for screening a substance which controls expression and/or oscillatory expression of Period2 gene, comprising the steps of:

allowing a suprachiasmatic nucleus section or peripheral tissue of the transgenic rat or mouse according to claim 16 to react with a substance to be tested, and

measuring activity of the reporter gene for oscillatory expression of the Period2 gene.

Assignments (2)
MERGER Recorded Sep 22, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016570/0324 →
MERGER Recorded Aug 29, 2005
From: YAMANOUCHI PHARMACEUTICAL CO., LTD.
To: ASTELLAS PHARMA INC.
Reel/Frame 016465/0289 →